Results 111 to 120 of about 4,565 (192)

Current knowledge about mechanisms of drug resistance against ALK inhibitors in non-small cell lung cancer [PDF]

, 2021
Jost, Philipp J., Lindenmann, Joerg, Pichler, Martin, Smolle, Elisabeth, Taucher, Valentin   +4 more
core   +1 more source

Targeted Therapy in NSCLC: A Comprehensive Review of Molecular Drivers and Treatment Strategies [PDF]

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide, with its management increasingly guided by molecular profiling and targeted therapies.
Kasianik , Viktoryia, Kiełbaszewska , Iga, Kowalczuk , Dmytro, Lazitskaya , Darya, Milasheuskaya, Valeryia, Miraniuk, Katsiaryna, Myrnyi , Andrii, Sobchynskyi , Mykola, Surosz , Natalia, Turlej , Kamil, Wiczkowski , Dawid   +10 more
core   +1 more source

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib

Lung Cancer: Targets and Therapy, 2017
Rohit K Jain, Hongbin Chen Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA Abstract: In the last decade, there have been major therapeutic advances in the management of patients with anaplastic lymphoma kinase (ALK)-positive ...
Jain RK, Chen H
doaj  

Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN-Associated and Sporadic NF2-Deficient Meningiomas. [PDF]

Cancer Res Commun
Chang LS, Oblinger JL, Wu LMN, Miller C, Burns SS.   +4 more
europepmc   +1 more source

Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial. [PDF]

Future Oncol
Ahn MJ, Delmonte A, Ghosh S, Hochmair M, Yang TY, Yang JC, Han JY, Hansen KH, Wu Y, Wan Y, Lin HM, Kretz J, Hupf B, Kurec AM, Churchill EN, Fram RJ, Cabasag CJ, Goriya V, Zhao Y, Campelo MRG.   +19 more
europepmc   +1 more source

Real-world first-line outcomes of alectinib and brigatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: a nationwide South Korean cohort study using the health insurance review and assessment data. [PDF]

Transl Lung Cancer Res
Kim HJ, Lee EA, Park JH, Lee HW.
europepmc   +1 more source

Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer [PDF]

, 2017
et al,, Govindan, Ramaswamy
core   +1 more source

Increased Cardiovascular Risk With Lorlatinib in Patients With ALK-Mutated Lung Cancer: A Real-World Comparative Study. [PDF]

J Am Heart Assoc
Lin CY, Su PL, Kuo CW, Tsai IL, Liu TH, Yang J, Lin CC, Lin SH.   +7 more
europepmc   +1 more source

Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis. [PDF]

Qual Life Res
Huang Y, Chu Q, Wang J, Zhang L.
europepmc   +1 more source

Hepatotoxicity of new-generation ALK inhibitors versus crizotinib in patients with non-small cell lung cancer: A systematic review and meta-analysis. [PDF]

iScience
Luo X, Du X, Chen Q, Wang C, Li L, He X, Gong Y, Chen J, Zhong X, Liu Y, Zhang X, Huang L.   +11 more
europepmc   +1 more source